NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply
+8 more ↓
59%
Finnrick rating
#448 of 500 ranked vendors
190 of 308 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Nexaph's purity-focus record is strongest on GHK-Cu and higher-volume Tirzepatide, with recent batches generally cleaner than the earlier volatile history. Weakness is concentrated in Semaglutide and Tesamorelin, where recurring sub-99.5% purity, identity or fill outliers, and mixed batch documentation keep results dispersed.

methodology →
vendor intelligence report
Vendor Intelligence Report: Nexaph

Nexaph's public pages point to Shanghai Nexa Pharma Co, Nevis terms, and an Indiana operating footprint without resolving the legal counterparty. The report maps shared COA infrastructure, sister-brand trails, crypto rails, and a documented batch-sterility thread.

39 pages9 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.25
89%
12
2
Tirzepatide
$1.13
77%
65
3
KLOW
$5.72
77%
3
4
Retatrutide
$2.46
76%
108
5
PT-141
-
72%
3
6
BPC-157
$1.51
64%
21
7
Ipamorelin
$1.30
60%
10
8
Cagrilintide
$3.50
51%
13
9
CJC-IPA
$3.96
45%
1
10
Tesamorelin
$2.88
37%
30
11
TB-500
$1.61
37%
7
12
Sermorelin
-
36%
3
13
CJC-1295
$3.40
35%
9
14
Semaglutide
$1.90
35%
15
15
MOTS-c
$1.88
29%
6
16
NAD+
$0.04
28%
3
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%26 Jun 2026: 57%26 Jun 2026: 57%1 Jul 2026: 57%1 Jul 2026: 57%13 Jul 2026: 57%17 Jul 2026: 57%20 Jul 2026: 57%21 Jul 2026: 57%4 Aug 2026: 57%9 Aug 2026: 57%13 Aug 2026: 57%27 Aug 2026: 57%4 Sep 2026: 57%9 Sep 2026: 57%10 Sep 2026: 57%10 Sep 2026: 57%10 Sep 2026: 57%14 Sep 2026: 57%15 Sep 2026: 57%16 Sep 2026: 57%16 Sep 2026: 57%17 Sep 2026: 57%17 Sep 2026: 57%18 Sep 2026: 57%20 Sep 2026: 57%24 Sep 2026: 57%24 Sep 2026: 57%25 Sep 2026: 58%1 Oct 2026: 58%5 Oct 2026: 58%9 Oct 2026: 58%13 Oct 2026: 58%20 Oct 2026: 58%23 Oct 2026: 58%23 Oct 2026: 58%27 Oct 2026: 58%29 Oct 2026: 58%2 Nov 2026: 58%2 Nov 2026: 58%6 Nov 2026: 58%17 Nov 2026: current 59%57%57%59%Jun 26Nov 26
Peptide testing

Ordered peptides from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply
Nexaph test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
6 Nov 2026
Pass
Retatrutide
lab nameView COA
2 Nov 2026
Pass
Tirzepatide
lab nameView COA
2 Nov 2026
Pass
Retatrutide
lab nameView COA
29 Oct 2026
Pass
KLOW
lab nameView COA
27 Oct 2026
Pass
Retatrutide
lab nameView COA
23 Oct 2026
Pass
Retatrutide
lab nameView COA
23 Oct 2026
Pass
Tirzepatide
lab nameView COA
20 Oct 2026
Pass
Retatrutide
lab nameView COA
13 Oct 2026
Pass
Tirzepatide
lab nameView COA
9 Oct 2026
Pass
GHK-Cu
lab nameView COA
1-10 of 200

About Nexaph test results from Finnrick

Nexaph is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 16 peptides and 309 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Nexaph peptides in this dataset are BPC-157 (21 tests) and Semaglutide (15 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply